$IMVT
Immunovant, Inc. Stock $imvt

$imvt Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000176401324000109 Filed on May 29, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2024
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$18.81M	$14.82M	$57.28M
YoY Change	22.11%	19.33%	19.29%
% of Gross Profit
Research & Development	$75.47M	$66.06M	$212.9M
YoY Change	49.23%	27.43%	32.87%
% of Gross Profit
Depreciation & Amortization	$80.00K	$64.00K	$231.0K
YoY Change	50.94%	18.52%	19.69%
% of Gross Profit
Operating Expenses	$94.28M	$80.88M	$282.7M
YoY Change	20.14%	25.86%	29.52%
Operating Profit
YoY Change
Interest Expense	$7.180M	$8.379M	$24.95M
YoY Change	76.63%	140.78%	229.22%
% of Operating Profit
Other Income/Expense, Net	$28.00K	-$2.587M	-$1.008M
YoY Change	-93.97%	-826.69%	298.42%
Pretax Income	-$87.07M	-$75.09M	-$258.8M
YoY Change	17.75%	24.27%	22.67%
Income Tax	$77.00K	$232.0K	$567.0K
% Of Pretax Income
Net Earnings	-$87.15M	-$75.32M	-$259.3M
YoY Change	17.87%	26.73%	22.93%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.60		-$1.88
Diluted Earnings Per Share	-$0.60	-$0.52	-$1.88
COMMON SHARES
Basic Shares Outstanding	146.1M shares	145.3M shares	138.1M shares
Diluted Shares Outstanding	146.1M shares		138.1M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2024
SHORT-TERM ASSETS
Cash & Short-Term Investments	$560.0M	$635.4M	$635.4M
YoY Change	69.72%	68.74%	68.74%
Cash & Equivalents	$560.0M	$635.4M
Short-Term Investments
Other Short-Term Assets	$26.63M	$24.90M	$24.90M
YoY Change	38.44%	-7.48%	-7.48%
Inventory
Prepaid Expenses	$26.63M	$24.90M
Receivables	$2.417M	$5.337M	$5.337M
Other Receivables	$0.00	$166.0K	$166.0K
Total Short-Term Assets	$589.0M	$665.8M	$665.8M
YoY Change	68.29%	64.66%	64.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$565.0K	$462.0K	$595.0K
YoY Change	73.85%	38.74%	-60.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00
YoY Change
Total Long-Term Assets	$631.0K	$595.0K	$595.0K
YoY Change	-47.72%	-60.47%	-60.47%
TOTAL ASSETS
Total Short-Term Assets	$589.0M	$665.8M	$665.8M
Total Long-Term Assets	$631.0K	$595.0K	$595.0K
Total Assets	$589.7M	$666.4M	$666.4M
YoY Change	67.89%	64.19%	64.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.04M	$7.155M	$7.155M
YoY Change	-58.29%	428.82%	428.82%
Accrued Expenses	$33.91M	$41.30M	$41.44M
YoY Change	41.43%	2.17%	-0.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$45.02M	$48.61M	$48.61M
YoY Change	-12.34%	12.27%	12.27%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$45.02M	$48.61M	$48.61M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$45.02M	$48.61M	$48.61M
YoY Change	-12.34%	12.14%	12.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$912.8M	-$825.7M
YoY Change	42.56%	45.81%
Common Stock	$14.00K	$14.00K
YoY Change	7.69%	7.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$544.7M	$617.8M	$617.8M
YoY Change
Total Liabilities & Shareholders Equity	$589.7M	$666.4M	$666.4M
YoY Change	67.89%	64.19%	64.19%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2024
OPERATING ACTIVITIES
Net Income	-$87.15M	-$75.32M	-$259.3M
YoY Change	17.87%	26.73%	22.93%
Depreciation, Depletion And Amortization	$80.00K	$64.00K	$231.0K
YoY Change	50.94%	18.52%	19.69%
Cash From Operating Activities	-$76.20M	-$59.70M	-$214.2M
YoY Change	60.86%	7.0%	13.83%
INVESTING ACTIVITIES
Capital Expenditures	$182.0K	$150.0K	$360.0K
YoY Change	304.44%	476.92%	82.74%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$182.0K	-$150.0K	-$360.0K
YoY Change	304.44%	476.92%	82.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$686.0K	1.545M	$472.4M
YoY Change	-22.92%	563.09%	566.47%
NET CHANGE
Cash From Operating Activities	-$76.20M	-59.70M	-$214.2M
Cash From Investing Activities	-$182.0K	-150.0K	-$360.0K
Cash From Financing Activities	$686.0K	1.545M	$472.4M
Net Change In Cash	-$75.36M	-58.30M	$258.8M
YoY Change	61.81%	4.89%	-320.69%
FREE CASH FLOW
Cash From Operating Activities	-$76.20M	-$59.70M	-$214.2M
Capital Expenditures	$182.0K	$150.0K	$360.0K
Free Cash Flow	-$76.38M	-$59.85M	-$214.6M
YoY Change	61.09%	7.22%	13.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001764013
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	imvt	Lease Agreement Additional Renew Period LeaseAgreementAdditionalRenewPeriod	P1Y
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-38906
CY2024	dei	Entity Registrant Name EntityRegistrantName	IMMUNOVANT, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-2771572
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	320 West 37th Street
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10018
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47000	usd
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	New York,
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2024	dei	City Area Code CityAreaCode	917
CY2024	dei	Local Phone Number LocalPhoneNumber	580-3099
CY2024	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2024	dei	Trading Symbol TradingSymbol	IMVT
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Public Float EntityPublicFloat	2176900000	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	146053941	shares
CY2024	dei	Auditor Firm AuditorFirmId	42
CY2024	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2024	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	635365000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	376532000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5337000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	700000	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	24902000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	26916000	usd
CY2024Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	166000	usd
CY2023Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	185000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	665770000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	404333000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	133000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1172000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	462000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	333000	usd
CY2024Q1	us-gaap	Assets Assets	666365000	usd
CY2023Q1	us-gaap	Assets Assets	405838000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	7155000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1353000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41300000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40421000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	138000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1173000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	15000	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	350000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	48608000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	43297000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2024Q1	us-gaap	Liabilities Liabilities	48608000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	43344000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.0001
CY2023Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	145582999	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	145582999	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	130329863	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	130329863	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	14000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1441518000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	927976000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1908000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	852000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-825683000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-566347000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	617757000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	362494000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	666365000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	405838000	usd
CY2024	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	212928000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	160257000	usd
CY2024	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	12500000	usd
CY2023	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	10000000	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57281000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48019000	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	282709000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	218276000	usd
CY2024	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	24948000	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	7578000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-253000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	567000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-259336000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-210960000	usd
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.88
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.88
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	138100577	shares
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	138100577	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	123075329	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	123075329	shares
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-259336000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-210960000	usd
CY2024	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1056000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	448000	usd
CY2024	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1056000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	448000	usd
CY2024	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-258280000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-117285000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-210512000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	469825000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	70228000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	657000	usd
CY2023	imvt	Adjustments To Additional Paid In Capital Contribution Share Based Compensation AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation	330000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	31966000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	448000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-210960000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	362494000	usd
CY2024	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	466733000	usd
CY2024	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5694000	usd
CY2024	imvt	Adjustments To Additional Paid In Capital Contribution Share Based Compensation AdjustmentsToAdditionalPaidInCapitalContributionShareBasedCompensation	103000	usd
CY2024	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	41013000	usd
CY2024	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1056000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-259336000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	617757000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-259336000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-210960000	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	41116000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	32296000	usd
CY2024	us-gaap	Depreciation Depreciation	231000	usd
CY2023	us-gaap	Depreciation Depreciation	193000	usd
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1130000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1131000	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4577000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11764000	usd
CY2024	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1558000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	20533000	usd
CY2024	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-19000	usd
CY2023	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-461000	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	5784000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-17124000	usd
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1349000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	15568000	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1172000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1145000	usd
CY2024	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-329000	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	156000	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-214227000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-188193000	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	360000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	197000	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-360000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-197000	usd
CY2024	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	6012000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	272000	usd
CY2024	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5694000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	657000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	472427000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	70885000	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	993000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	220000	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	258833000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	376532000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	493817000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	635365000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	376532000	usd
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	91000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	509000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	635400000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-825700000	usd
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[B] Use of Estimates</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, stock-based compensation, litigation accruals, clinical trial accruals, operating leases, research and development costs and income taxes. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, the Company assessed the impact of the post-COVID-19 environment, geopolitical tensions and global slowdown of economic activity, changes in inflation, heightened interest rates and a potential recession in the U.S. on its operations and financial results as of March 31, 2024 and through the issuance of this report. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact that these uncertainties may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses.</span></div>
CY2024	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">[D] Concentration of Credit Risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. As of March 31, 2024, the cash and cash equivalents balance is kept in banking institutions that the Company believes are of high credit quality and are in excess of federally insured levels. The Company maintains its cash and cash equivalents with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash and cash equivalents.</span></div>
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	465000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	572000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1457000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	998000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41300000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	40421000	usd
CY2024	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	600000	usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	400000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16502386	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15385460	shares
CY2017Q4	imvt	Upfront Payments UpfrontPayments	30000000	usd
CY2017Q4	imvt	Percentage Of Research And Development Costs PercentageOfResearchAndDevelopmentCosts	0.50
CY2024Q1	imvt	Cumulative Milestone Payments CumulativeMilestonePayments	32500000	usd
CY2018Q4	imvt	Sub Licensed Agreement Aggregate Purchase Price SubLicensedAgreementAggregatePurchasePrice	37800000	usd
CY2023Q2	imvt	Milestone Payments MilestonePayments	12500000	usd
CY2022Q4	imvt	Milestone Payments MilestonePayments	10000000.0	usd
CY2024Q1	imvt	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	24634000	usd
CY2023Q1	imvt	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	31321000	usd
CY2024Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	14744000	usd
CY2023Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	7530000	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-258769000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-210951000	usd
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	567000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9000	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	567000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	usd
CY2024	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-54341000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-44300000	usd
CY2024	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	19321000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	14569000	usd
CY2024	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	8096000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4798000	usd
CY2024	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	46389000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	31944000	usd
CY2024	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	7518000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	3632000	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-9204000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	-1960000	usd
CY2024	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1020000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	922000	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	567000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	usd
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0022
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2024Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	10000	shares
CY2023Q1	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	10000	shares
CY2024Q1	imvt	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Including Shares Not Yet Settled Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIncludingSharesNotYetSettledNumber	13050172	shares
CY2023Q1	imvt	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Including Shares Not Yet Settled Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIncludingSharesNotYetSettledNumber	11682481	shares
CY2024Q1	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	9865000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	8112000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	98248000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	64418000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	9110000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7120000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	21245000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	10798000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3363000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2042000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	141831000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	92490000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	141484000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	91988000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	347000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	502000	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	74000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	69000	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	39000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	250000	usd
CY2024Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	234000	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	183000	usd
CY2024Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	347000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	502000	usd
CY2024Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q1	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2024Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	141500000	usd
CY2023Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	92000000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	imvt	Common Stock Votes Per Share CommonStockVotesPerShare	1	vote
CY2023Q4	imvt	Sale Of Stock Percentage Of Proceeds Owed Through Sales Agreement SaleOfStockPercentageOfProceedsOwedThroughSalesAgreement	0.03
CY2023Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	38.00
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	145582999	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2090367	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	590317	shares
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	19249818	shares
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	16340576	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5213194	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11682481	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.05
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M28D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	88919000	usd
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2398263	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	18.01
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	795913	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.30
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	252279	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	11.96
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	6223	shares
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.24
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13026329	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.85
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M3D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	293920000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7518395	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	8.30
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y8M26D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	180535000	usd
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M9D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	41013000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	31966000	usd
CY2020Q2	imvt	Number Of Sublease Agreements NumberOfSubleaseAgreements	2	agreement
CY2020Q2	imvt	Number Of Office Space Floors NumberOfOfficeSpaceFloors	2	floor
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y8M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2024Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.054
CY2023Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.039
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1200000	usd
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	1200000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	141000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	141000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	138000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001764013-24-000109-index-headers.html	Edgar Link	pending
0001764013-24-000109-index.html	Edgar Link	pending
0001764013-24-000109.txt	Edgar Link	pending
0001764013-24-000109-xbrl.zip	Edgar Link	pending
exhibit231-20240331.htm	Edgar Link	pending
exhibit311-20240331.htm	Edgar Link	pending
exhibit312-20240331.htm	Edgar Link	pending
exhibit321-20240331.htm	Edgar Link	pending
exhibit322-20240331.htm	Edgar Link	pending
exhibit971-20240331.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
imvt-20240331.htm	Edgar Link	pending
imvt-20240331.xsd	Edgar Link	pending
imvt-20240331_g1.jpg	Edgar Link	pending
imvt-20240331_g2.jpg	Edgar Link	pending
imvt-20240331_g3.jpg	Edgar Link	pending
imvt-20240331_g4.jpg	Edgar Link	pending
imvt-20240331_g5.jpg	Edgar Link	pending
imvt-20240331_g6.jpg	Edgar Link	pending
imvt-20240331_g7.jpg	Edgar Link	pending
imvt-20240331_g8.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
imvt-20240331_def.xml	Edgar Link	unprocessable
imvt-20240331_lab.xml	Edgar Link	unprocessable
imvt-20240331_pre.xml	Edgar Link	unprocessable
imvt-20240331_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
imvt-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IMVT
Immunovant, Inc. Stock $imvt

2024 Q2 Form 10-K Financial Statement

#000176401324000109 Filed on May 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMVT Immunovant, Inc. Stock $imvt

2024 Q2 Form 10-K Financial Statement

#000176401324000109 Filed on May 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IMVT
Immunovant, Inc. Stock $imvt